Pharmaceutical ProductCached Profile
CARTO 3
Active Ingredients (Generic):Unmapped
Therapeutic Area: Cardiology
LIFETIME PROMOTIONAL SPEND
$494,552
General Payments Aggregated (2021–2025)
Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.
FDA Patient Safety Profile
Dynamic safety indicators compiled from official FDA product labels.
Active Clinical Trials
Clinical studies listing this drug as an active intervention.
Three-Dimensional Electroanatomical Mapping Versus Conventional Fluoroscopy-Guided Slow Pathway Ablation for Typical Atrioventricular Nodal Re-Entrant Tachycardia: A Prospective Randomized Study
COMPLETEDPhase NANCT07630480
VOYAGE- Ventricular Tachycardia Ablation and Myocardial Scar Characterization With Magnetic Resonance
COMPLETEDPhase PHASE4NCT04694079
Ablation of Persistent Atrial Fibrillation Based on High Density Voltage Mapping and Complex Fractionated Atrial Electrogram
COMPLETEDPhase NANCT03046043
Top Funded Physicians (Cumulative)
Doctors receiving the highest aggregate promotional support for this product.
Dr. FERMIN GARCIAMedical Doctor$16,439
Dr. JOSHUA SILVERSTEINMedical Doctor$15,515
Dr. WARREN JACKMANMedical Doctor$14,221
Dr. SHEPHAL DOSHIMedical Doctor$13,291
Dr. ALEXANDRU COSTEAMedical Doctor$12,429
Drug Marketing Payments Log
Federal registry records of promotional speaking, consulting, meals, and offsets.
Year:
2025
2025
2024
2023
2022
2021
Querying Open Payments Database
Fetching live CMS.gov records for CARTO 3...